Breakpoint Therapeutics is developing targeted cancer therapies that modulate DNA damage response (DDR) pathways.
Through precise interference with DNA repair, our drug candidates are designed to kill cancer cells without harming healthy cells. We leverage new insights and the concept of synthetic lethality to increase the therapeutic window and achieve better outcomes for patients with therapy-resistant and hard-to-treat cancers.
Our innovative programs are based on foundational science and benefit from the class-leading expertise of our research and development partners, including Evotec SE.
In addition to a worldwide network of collaborators, Breakpoint has support from visionary life science investors Medicxi, Taiho Ventures, Evotec and BVF Partners.